Voxtalisib

From Wikipedia, the free encyclopedia
Voxtalisib
Voxtalisib structure.png
Identifiers
  • 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
Chemical and physical data
FormulaC13H14N6O
Molar mass270.296 g·mol−1
3D model (JSmol)
  • CCN1C2=NC(=NC(=C2C=C(C1=O)C3=CC=NN3)C)N
  • InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)
  • Key:RGHYDLZMTYDBDT-UHFFFAOYSA-N

Voxtalisib (XL-765, SAR245409) is a drug which acts as a dual inhibitor of the kinase enzymes phosphatidylinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR). It is in clinical trials for the treatment of various types of cancer.[1][2][3][4][5]

References[]

  1. ^ Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, et al. (April 2011). "Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide". Neuro-Oncology. 13 (4): 384–92. doi:10.1093/neuonc/noq193. PMC 3064692. PMID 21317208.
  2. ^ Gravina GL, Mancini A, Scarsella L, Colapietro A, Jitariuc A, Vitale F, et al. (January 2016). "Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models". Tumour Biology. 37 (1): 341–51. doi:10.1007/s13277-015-3725-3. PMID 26219891. S2CID 23993969.
  3. ^ Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, et al. (April 2018). "Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial". The Lancet. Haematology. 5 (4): e170–e180. doi:10.1016/S2352-3026(18)30030-9. PMC 7029813. PMID 29550382.
  4. ^ Rehan M (2019). "Anticancer compound XL765 as PI3K/mTOR dual inhibitor: A structural insight into the inhibitory mechanism using computational approaches". PLOS ONE. 14 (6): e0219180. Bibcode:2019PLoSO..1419180R. doi:10.1371/journal.pone.0219180. PMC 6597235. PMID 31247018.
  5. ^ Tarantelli C, Lupia A, Stathis A, Bertoni F (February 2020). "Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?". International Journal of Molecular Sciences. 21 (3): 1060. doi:10.3390/ijms21031060. PMC 7037719. PMID 32033478.
Retrieved from ""